SEARCH

SEARCH BY CITATION

References

  • 1
    Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. A low dose of a new proton pump inhibitor LY307640 (E3810) effectively inhibits acid secretion in humans. Gastroenterology 1996; 110: A161(Abstract).
  • 2
    Blanshard C, Millson C, Sercombe J, Pounder RE. The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
  • 3
    Dammann HG, Burkhardt F, Bell NE, Bjaaland T. Rabeprazole effectively inhibits 24-hour H+ activity and nocturnal acid secretion in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
  • 4
    Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. Arch Intern Med 1991; 151: 2394 400.
  • 5
    Wesdorp ICE, Dekker W, Festen HPM. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux oesophagitis. Dig Dis Sci 1993; 38: 2287 92.
  • 6
    Cloud ML, Enas N, Humphries TJ. Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled dose–response clinical trials in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993 1000.
  • 7
    Humphries TJ, Nardi RV, Lazar JD, Spanyers SA. Drug–drug interaction evaluation of rabeprazole sodium: a clean/expected slate? Gut 1996; 39(Suppl. 3): A47(Abstract).
  • 8
    Wilde MI & McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91 132.
  • 9
    Hetzel DJ, Dent J, Reed WD, Narielvala FM, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903 12.
  • 10
    Donner A. Approaches to sample size estimation in the design of clinical trials—a review. Stat Med 1984; 3: 199 214.
  • 11
    Casagrande JP, Pike MC, Smith PG. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometric 1978; 34(3): 483 6.
  • 12
    Feldman M & Burton ME. Histamine 2-receptor antagonists: standard therapy for acid diseases. N Engl J Med 1990; 323: 1749 55.
  • 13
    Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastro-oesophageal reflux disease. Gastroenterology 1990; 98: 654 61.
  • 14
    Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 3 7.
  • 15
    Robinson M, Maton PN, Rodriguez S, Greenwood B, Humphries TJ. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 4: 973 80.
  • 16
    McTavish D, Buckley MMT, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991; 42: 138 70.
  • 17
    Mee AS & Rowley JL & the Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757 63.
  • 18
    Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM & the Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749 57.
  • 19
    Earnest DL, Dorsch E, Jones J, Jennings DE, Greski-Rose PA. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998; 93: 238 43.
    Direct Link:
  • 20
    Mossner J, Holscher AH, Herz R, Schneiders A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321 6.
  • 21
    Corinaldesi R, Valentini M, Belaiche J, Colin R, Geldof H, Maier C & the European Pantoprazole Study Group. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995; 9: 667 71.